Alvotech and Teva Announce U.S. Approval of SIMLANDI® (

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...

Related Keywords

Canada , New Zealand , Israel , Iceland , Australia , United States , Switzerland , India , Vietnam , Republic Of , Indonesia , Japan , South Africa , Ukraine , Thailand , Bangladesh , Malaysia , Taiwan , South Korea , Reykjavik , C10 , Pakistan , Yangtze River , China General , China , Cambodia , Singapore , Turkey , Philippines , Hong Kong , America , Yael Ashman , Sanjeev Sharma , Abdi Ibrahim , Robert Wessman , Yonatan Beker , Kelley Dougherty , Eden Klein , Eric Hughes , Fuji Pharma Co Ltd , Abbvie Biotechnology Ltd , Pharma Corporation , Lotus Pharmaceuticals Co Ltd , Teva Pharmaceutical Industries Ltd , Globenewswire Inc , Teva Pharmaceuticals , Yangtze River Pharmaceutical Group Co Ltd , Alvotech Holdings , Oaktree Acquisition Corp , Drug Administration , Global Communications , Kamada Ltd , Pharmaceutical Industries , Chief Medical Officer , Abbvie Full Year , Fourth Quarter , Advanz Pharma , Cipla Med Pro , River Pharmaceutical , Idiopathic Arthritis , Prescribing Information , Private Securities Litigation Reform Act , Note Regarding Forward Looking , Annual Report , Looking Statements , Markets ,